Delayed treatments, canceled doctor visits and skipped prescriptions: Researchers say all will increase because of the tax ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...

Thomaston considers a $111,000 study to address declining school enrollment and aging buildings, where options are closing schools or regionalizing.

The company successfully completed enrollment in the INTEGRA-D™ Pivotal Trial. This marks a significant milestone in the journey to introduce the CCM-D® HF System, the world’s first device ...

A deal between Columbia University and the Trump administration calls for the Ivy League school to pay more than $220 million to resolve multiple federal investigations into alleged violations ...

"Completing enrollment in our Phase 3 HARBOR study for del-desiran marks a significant step toward bringing the first potentially approved drug for DM1 to people around the world who are living ...

The company successfully completed enrollment in the INTEGRA-D™ Pivotal Trial. This marks a significant milestone in the journey to introduce the CCM-D® HF System, the world’s first device combining ...

We know what these phones look like since their leaked renders revealed their design, and ahead of the launch, Google decided to corroborate the design leak of the Pixel 10 Pro by dropping a 13 ...

Nachrichten»Impulse Dynamics Completes Enrollment of Pivotal Trial for CCM-D HF System and Earns Category 1 CPT Codes for CCM Therapy 28.07.2025 14:10 Uhr 242 Leser Artikel bewerten: (1) ...

"Completing enrollment in our Phase 3 HARBOR study for del-desiran marks a significant step toward bringing the first potentially approved drug for DM1 to people around the world who are living ...

CLSS uses two modes— Design Mode and Refine Mode to manage how schedules are built and updated. While both modes use the same CLSS tools, they differ in where data is stored, who is involved in ...